
Sign up to save your podcasts
Or


Venrock partner Andrew Gottesdiener speaks with Jigar Raythatha, former CEO of Constellation Pharmaceuticals, about lessons learned from his time at Constellation. As Constellation has evolved from an early-stage company to being acquired by MorphoSys, Raythatha dives into its many life-cycles, his heavy involvement in the recruitment process, and the decision to conduct a PIPE financing. Raythatha also shares the characteristics to look for in an investor syndicate and the challenges of scaling a public company.
By Venrock, a venture capital firm4.8
6262 ratings
Venrock partner Andrew Gottesdiener speaks with Jigar Raythatha, former CEO of Constellation Pharmaceuticals, about lessons learned from his time at Constellation. As Constellation has evolved from an early-stage company to being acquired by MorphoSys, Raythatha dives into its many life-cycles, his heavy involvement in the recruitment process, and the decision to conduct a PIPE financing. Raythatha also shares the characteristics to look for in an investor syndicate and the challenges of scaling a public company.

1,290 Listeners

2,671 Listeners

2,444 Listeners

1,100 Listeners

341 Listeners

324 Listeners

396 Listeners

5,522 Listeners

9,902 Listeners

34 Listeners

506 Listeners

19 Listeners

265 Listeners

521 Listeners

1,356 Listeners